We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Circassia Group Plc | LSE:CIR | London | Ordinary Share | GB00BJVD3B28 | ORD 0.08P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 34.00 | 33.10 | 34.90 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCIR
RNS Number : 0341K
Circassia Pharmaceuticals Plc
10 December 2018
CIRCASSIA PHARMACEUTICALS PLC
POSTING OF SHAREHOLDER CIRCULAR
Oxford, UK - 10 December 2018: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that further to the announcement earlier today, a Circular has been published and will be posted to shareholders today in relation to the proposed cancellation of ordinary shares from the Official List and Admission to trading on AIM. The Circular contains the notice convening the General Meeting to be held at the offices of Circassia Pharmaceuticals plc, Northbrook House, Robert Robinson Avenue, The Oxford Science Park, Oxford, Oxfordshire, OX4 4GA, United Kingdom at 12 midday on 4 January 2019.
A copy of the Circular will shortly be available on the Company's website at www.circassia.com.
Enquiries
Circassia Steve Harris, Chief Executive Officer Tel: +44 (0) 1865 405 560 Julien Cotta, Chief Financial Officer Rob Budge, Corporate Communications Peel Hunt James Steel / Dr. Christopher Golden Tel: +44 (0) 20 7418 8900 Numis Securities James Black / Freddie Barnfield Tel: +44 (0) 20 7260 1000 FTI Consulting Simon Conway / Mo Noonan Tel: +44 (0) 20 3727 1000
About Circassia
Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX(R) asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners. In 2017, the Company established a commercial collaboration with AstraZeneca in the United States in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza(R) and has the commercial rights to NDA-stage COPD product Duaklir(R). For more information please visit www.circassia.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
CIRURVBRWSAUAAA
(END) Dow Jones Newswires
December 10, 2018 12:59 ET (17:59 GMT)
1 Year Circassia Chart |
1 Month Circassia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions